

# Cell & Gene Therapy Outsourcing Process Development



Half of respondents who outsource cell and/or gene manufacturing activities to CDMOs are outsourcing process development to ensure the ability to scale-up manufacturing should the therapy advance towards commercialization. Respondents from large biopharma companies are slightly more likely to outsource this activity in the near future when compared to respondents from nonlarge biopharma companies (52% vs 45%).

*“Which of the following manufacturing activities and services will your company outsource to CDMOs in the next 18 months?” (n=101)*

## Process Development / Scalable Manufacturing Process by Company Size

